0001477932-26-002140
SEC filingASP Isotopes Inc. provided a business update highlighting first commercial shipments expected in 2026 across multiple isotopes, Phase 1 helium capacity in Q3 2026, and a long-term EBITDA target exceeding $300 million in 2031.
ASP Isotopes Inc. announced significant operational progress across its nuclear medicine, electronics, and nuclear energy platforms, positioning 2026 as a pivotal year for commercial scale-up. In nuclear medicine, Ytterbium-176 shipments are targeted for mid-2026 following recovery from a 2025 power surge incident, while Carbon-14 awaits final feedstock for imminent commercial launch under a $2.5 million annual take-or-pay agreement. Radiopharmaceuticals via PET Labs show robust demand with a second cyclotron operational and U.S. expansion through Florida and South Carolina acquisitions, driving targeted revenue doubling to $10 million in 2026. Electronics progress includes Si-28 sample shipments validated by customers and plant optimizations, with Q2 2026 commercial shipments ahead. The Virginia Gas Project, post-Renergen acquisition, achieved Phase 1 drilling four months early, confirming strong flow rates and on track for Q3 helium and LNG capacity. Financially, 2025 product revenue grew 46% to $5.7 million from radiopharmacy gains, supported by a fortified $333 million cash position from $345 million raises. The >$300 million 2031 EBITDA target underscores execution focus, bolstered by Quantum Leap Energy advancements including SEC filing, NECSA contract, and U.S. partnerships. Investors should note forward-looking risks including feedstock timing, regulatory approvals, and execution dependencies as outlined in safe harbor statements.